[Which action mechanisms are secured in the treatment of radiogenic side effects by hyperbaric oxygenation? Comment on the article by A. Hartmann, M. Almeling, U. M. Carl, Hyperbaric oxygenation (HBO) in the treatment of radiogenic side effects, Strahlenther Onkol l996, 172, 641-8 (No. 12)].
Thilmann
C
C
Adamietz
I A
IA
Böttcher
H D
HD
D043925:Angiogenesis Inducing Agents; D000818:Animals; D002478:Cells, Cultured; D006801:Humans; D006931:Hyperbaric Oxygenation; D018919:Neovascularization, Physiologic; D010025:Osteoradionecrosis / Q000628:therapy; D011832:Radiation Injuries / Q000628:therapy*; D011833:Radiation Injuries, Experimental / Q000628:therapy; D051381:Rats
D043925:Angiogenesis Inducing Agents
Welche Wirkmechanismen sind gesichert bei der Behandlung radiogener Nebenwirkungen durch hyperbare Oxygenierung? Zu dem Beitrag von A. Hartmann, M. Almeling, U. M. Carl: Hyperbare Oxygenierung (HBO) zur Behandlung radiogener Nebenwirkungen: Strahlenther Onkol 1996;172:641-8 (Nr. 12).